Legacy Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Legacy Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$342K	Hold	42,500	–	–	0.04%	304
2024 Q4	$382K	Hold	42,500	–	–	0.04%	282
2024 Q3	$312K	Hold	42,500	–	–	0.03%	294
2024 Q2	$243K	Hold	42,500	–	–	0.03%	285
2024 Q1	$213K	Hold	42,500	–	–	0.03%	292
2023 Q4	$382K	Hold	42,500	–	–	0.05%	216
2023 Q3	$330K	Hold	42,500	–	–	0.05%	226
2023 Q2	$411K	Hold	42,500	–	–	0.06%	190
2023 Q1	$466K	Hold	42,500	–	–	0.09%	156
2022 Q4	$184K	Hold	42,500	–	–	0.03%	235
2022 Q3	$320K	Buy	+42,500	New	+$368K	0.07%	166

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Legacy Advisors's AUPH Position: Q1 2025 in Review

Legacy Advisors held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2025 at 42,500 shares worth $342K. The position accounts for 0.04% of the portfolio, ranked #304.

Legacy Advisors first reported a position in AUPH in Q3 2022 and has held it in 11 quarters since. The position peaked at $466K in Q1 2023. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

Legacy Advisors held 42,500 shares of Aurinia Pharmaceuticals worth $342K as of Q1 2025.
Legacy Advisors left its Aurinia Pharmaceuticals share count unchanged in Q1 2025.
Aurinia Pharmaceuticals made up 0.04% of Legacy Advisors's portfolio in Q1 2025, its #304 holding.
Legacy Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
Legacy Advisors's Aurinia Pharmaceuticals position peaked at $466K in Q1 2023.
214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on Legacy Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.